Press release
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing
About this update from Compass Therapeutics, Inc.
[{"type":"text","content":"BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as membership and inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. “We are pleased to be added to the Russell Indexes,” said Vered Bisker-Leib, President & COO of Compass Therapeutics. “The inclusion of Compass will enhance trading activity of our stock and broaden our exposure to the investment community, which may help accelerate our efforts to develop next generation antibodies into transformative cancer therapies that improve patients’ lives.” Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information about the Russell U.S. Indexes and the Russell index reconstitutions, visit the FTSE Russell website. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evad...